Tyra Biosciences

TYRA Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-02

Catalyst timeline

BridgeBio infigratinib competitor NDA filing2H 2026BridgeBio infigratinib competitor NDA filing, 2H 2026, notable
Dabogratinib NMIBC interimAug 2026Dabogratinib NMIBC interim, Aug 2026, major
SURF302 IR readoutSep 2026SURF302 IR readout, Sep 2026, notable
Dabogratinib ACH interim4Q 2026Dabogratinib ACH interim, 4Q 2026, material
Dabogratinib readout2027Dabogratinib readout, 2027, notable
BEACH301 Achondroplasia readoutlate 1Q 2027BEACH301 Achondroplasia readout, late 1Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

dabogratinib

TYRA-300

Small Molecule Target: FGFR3

Low-Grade Upper Tract Urothelial Carcinoma Phase 2 Phase 2a/b trial oral NCT06995677
Non-Muscle Invasive Bladder Cancer Phase 2 oral NCT05544552
Achondroplasia Phase 2 oral NCT06842355

TYRA-430

Small Molecule Target: FGFR4, FGFR3

Hepatocellular Carcinoma Phase 1 oral NCT06915753

TYRA-200

Small Molecule Target: FGFR1, FGFR2, FGFR3

Intrahepatic Cholangiocarcinoma Phase 1 oral NCT06160752

Technology platforms

SNAP

Proprietary precision medicine platform enabling rapid and precise drug design through iterative molecular SNAPshots using protein crystallography, cell-based assays, and in vivo models. Applied to FGFR biology and other targets for oncology and rare/genetically defined conditions.

Targets: FGFR3, FGFR4, FGFR2, FGFR1, FGFR

Discontinued (1)

dabogratinib — Metastatic Urothelial Carcinoma · no further development planned due to prioritized focus on more attractive market opportunities

Biotech Distilled coverage (2)

2026-08-05 UPDATE: Tyra Biosciences (TYRA) - The Catalyst Slips Again, and the ATM Gets Reloaded 🔒 Paid
2026-06-11 Tyra Biosciences (TYRA) — Scientific Deep Dive for Dabogratinib (TYRA-300) and the FGFR Pipeline

Articles open on Substack. Some deep dives are subscriber-only.